Group 1: Innovative Drug Development - The company has established a multi-mode, positive cycle research and development ecosystem, focusing on metabolic diseases and respiratory diseases, with two innovative drug projects approved for market and several in clinical trials [2][4]. - ZSP1601 tablets, targeting metabolic dysfunction-related fatty liver disease (MASH), have shown significant reduction in liver inflammation markers after four weeks of treatment, indicating potential for improving liver inflammation and fibrosis [2][4]. - RAY1225 injection, a long-acting GLP-1 class drug, has completed Phase II clinical trials for obesity and type 2 diabetes, achieving primary endpoints and demonstrating significant weight loss and metabolic improvements [4][14][18]. Group 2: Clinical Trial Results - RAY1225 injection demonstrated a weight loss of -10.05%, -12.98%, and -15.05% for 3mg, 6mg, and 9mg doses respectively, significantly outperforming the placebo group [14][16]. - The RAY1225 injection also showed a reduction in HbA1c levels of -1.68%, -2.06%, and -2.16% for the same doses, with a notable percentage of participants achieving target HbA1c levels [16][18]. - The clinical trial for the oral antiviral drug, Liratewe tablets, has been approved and included in the national medical insurance directory, providing accessible treatment options for patients [5][6]. Group 3: Safety and Efficacy - The clinical trials for RAY1225 injection reported good safety and tolerability, with low incidence of gastrointestinal adverse effects, similar to previous GLP-1 drug profiles [18]. - The clinical trial for Anglave tablets showed a median flu symptom relief time of 31.72 hours, with no serious adverse events reported, indicating good safety and efficacy in children and adolescents [10][11]. - Anglave tablets demonstrated a significant reduction in flu symptoms compared to placebo, achieving statistical significance in symptom relief and viral load reduction [10][11]. Group 4: Research and Development Investment - The company has consistently invested over 8% of its annual revenue in R&D, with the last three years exceeding 10%, reflecting a commitment to innovation and development [19]. - The R&D strategy includes a diversified matrix of traditional Chinese medicine, innovative drugs, modified new drugs, chemical generics, and raw materials, transitioning from a traditional to an innovative pharmaceutical enterprise [19].

Group 1 - The vitamin sector has seen a rise of 2.34%, ranking 9th among concept sectors, with 62 stocks increasing in value [1][2] - Notable gainers include Nonnawell, Fengyuan Pharmaceutical, and Nengte Technology, which reached the daily limit, while Minsheng Health, Zhenhua Co., and Erkang Pharmaceutical also showed significant increases of 8.75%, 7.15%, and 6.69% respectively [1][2] - The sector experienced a net inflow of 5.92 billion yuan from main funds, with 43 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2][3] Group 2 - The top stocks by net inflow include Nonnawell with 925.69 million yuan, followed by Fengyuan Pharmaceutical with 884.21 million yuan, and Zhongsheng Pharmaceutical with 728.46 million yuan [2][3] - The net inflow ratios for Fengyuan Pharmaceutical, Nengte Technology, and Huate Dain are 24.78%, 19.08%, and 14.28% respectively, indicating strong investor interest [3] - Stocks such as Dongbao Biological, Huate Dain, and Huaheng Biological experienced declines of 3.71%, 2.04%, and 0.91% respectively, highlighting some volatility within the sector [1][5]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - The innovative drug, Olanidavir, is the world's first targeted antiviral for influenza, developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., in collaboration with Guangzhou National Laboratory and the team led by Academician Zhong Nanshan [1] - Olanidavir has advantages such as rapid onset, strong antiviral effects, and low resistance, providing a new treatment option for influenza [1] - The drug has received patent authorization in multiple countries, including China and the United States, and has been recognized in top international academic journals [1] Group 2 - JD Health has established itself as the leading platform for the online launch of new specialty drugs, leveraging its strong supply chain infrastructure [2] - The company emphasizes a comprehensive solution for influenza treatment by integrating medical services, testing, diagnosis, and medication [2] - JD Health plans to continue collaborating with global pharmaceutical partners to enhance the accessibility of new specialty drugs for patients [2]

证券代码：002317 公告编号：2025-067 广东众生药业股份有限公司 关于签订募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 6 月 6 日召开第 八届董事会第二十二次会议、第八届监事会第二十二次会议，于 2025 年 6 月 23 日召开 2025 年第二次临时股东大会，审议通过了《关于变更部分募集资金用途 的议案》。公司于 2025 年 6 月 24 日召开第八届董事会第二十三次会议、第八届 监事会第二十三次会议，审议通过了《关于开设募集资金专项账户的议案》。具 体详见公司在巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 基于部分募投项目变更，为规范公司募集资金管理、存放和使用，切实保护 投资者权益，根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》等相关法律法规及公司《募集资 金管理制度》的有关规定，公司及公司控股子公司广东众生睿创生物科技有限公 司（以下简称"众生睿创"）开设了新的募 ...

Core Viewpoint - The article highlights the promising results of RAY1225, a novel GLP-1/GIP dual receptor agonist developed by Zhongsheng Pharmaceutical, showcasing its efficacy and safety in treating overweight, obesity, and type 2 diabetes during the ADA conference [2][5]. Group 1: Clinical Results - RAY1225 demonstrated significant weight loss effects, with an average reduction exceeding 10% in all dosage groups by week 10, and over 15% in the 9mg group by week 24 [2]. - Approximately 95.1% of participants achieved a weight loss of 5% or more by week 24, indicating strong efficacy [2]. - The gastrointestinal side effects associated with RAY1225 were mostly mild, with lower incidence rates of diarrhea, nausea, and vomiting compared to Tirzepatide [3]. Group 2: Administration and Compliance - RAY1225 is administered bi-weekly, which is more convenient than the weekly injection schedule of Tirzepatide, potentially improving patient adherence to the treatment [4]. Group 3: Ongoing Research - The Phase III clinical trial (REBUILDING-2) for RAY1225 has commenced, featuring a multi-center, randomized, double-blind, placebo-controlled design, with ethical approval obtained from relevant institutions [5].

Core Viewpoint - The company has approved the use of raised funds to provide loans to its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., for the implementation of a new drug research and development project, amounting to a maximum of RMB 110 million [1][2][10]. Summary of Relevant Sections Fundraising Overview - The company raised a net amount of RMB 590.20 million after deducting issuance costs of RMB 8.37 million, as approved by the China Securities Regulatory Commission [1][2]. - The funds were deposited into a designated account on June 15, 2023, and verified by an accounting firm [1]. Changes in Fund Usage - The company decided to reduce the budget for the "Anti-tumor Drug R&D Project" from RMB 169.20 million to RMB 43.26 million, reallocating the reduced amount of RMB 125.94 million to the "Drug R&D Center and Supporting Facilities Construction Project" [1][2]. - The remaining unused funds from the "Anti-tumor Drug R&D Project" and "Digital Platform Upgrade Project" totaling RMB 103.08 million will now be used for the new drug R&D project at the subsidiary [2][5]. Loan Details - The loan to the subsidiary will be provided in stages based on actual project needs, with a term of 5 years and an interest rate referencing the Loan Prime Rate (LPR) [1][2][10]. - The board of directors has authorized the chairman or designated agents to handle related matters and sign necessary documents [1][10]. Financial Status of the Subsidiary - As of March 31, 2025, the subsidiary had total assets of RMB 670.36 million and total liabilities of RMB 219.90 million, resulting in net assets of RMB 450.46 million [11]. - The subsidiary reported a total revenue of RMB 125.27 million for the first quarter of 2025, with a net loss of RMB 528.35 million for the same period [11]. Related Party Transactions - The loan constitutes a related party transaction, as the subsidiary is controlled by the company, and the terms are deemed fair and reasonable [8][9][10]. - The independent directors and supervisory board have approved the transaction, confirming it aligns with legal regulations and does not harm the interests of shareholders [14][15].

证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法 律法规及规范性文件的有关规定，广东众生药业股份有限公司（以下简称"公司"） 第八届董事会独立董事专门会议 2025 年第四次会议于 2025 年 6 月 24 日在公司 会议室以通讯方式召开。本次会议应出席独立董事 3 人，实际出席独立董事 3 人。 经全体独立董事推举，本次会议由独立董事牟小容女士召集并主持。全体独立董 事本着认真、负责的态度，对公司相关议案及事项进行了审议并发表审核意见如 下： 一、会议以 3 票同意，0 票反对，0 票弃权的表决结果，审议通过了《关于 使用募集资金向控股子公司提供借款实施募投项目暨关联交易的议案》。 公司独立董事一致认为：本次公司使用募集资金向控股子公司提供借款实施 募投项目暨关联交易的事项符合《上市公司募集资金监管规则》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市 公司规范运作》等法律法规、规范性文件的规定，有利于保障募投项目的顺利实 施，符合公司及公司控股子公司广东众生睿创生物科技有限公司的实际情况，不 存在变相改变募集资金用途或损害公司股东尤其是中小 ...

证券代码：002317 公告编号：2025-064 广东众生药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 备 注 ： 具 体 内 容 详 见 信 息 披 露 媒 体 ：《 证 券 时 报 》 和 巨 潮 资 讯 网 （www.cninfo.com.cn）。 证券代码：002317 公告编号：2025-064 二、《关于开设募集资金专项账户的议案》。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十三次 会议的会议通知于 2025 年 6 月 17 日以专人和电子邮件方式送达全体董事，会议 于 2025 年 6 月 24 日在公司会议室以现场和通讯表决方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监事、 董事会秘书列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的 有关规定。经与会董事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《关于使用募集资金向控股子公司提供借款实施募投项目暨 关联交易的议案》。 基于部分募投项目变更，为保障项目顺利实施，同意公司使 ...

一、公司募集资金的情况概述 证券代码：002317 公告编号：2025-066 广东众生药业股份有限公司 关于使用募集资金向控股子公司 提供借款实施募投项目暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 6 月 24 日召开 了第八届董事会第二十三次会议及第八届监事会第二十三次会议，审议通过了 《关于使用募集资金向控股子公司提供借款实施募投项目暨关联交易的议案》， 同意公司使用募集资金向公司控股子公司广东众生睿创生物科技有限公司（以下 简称"众生睿创"）提供借款，借款总金额不超过人民币 11,000.00 万元，本次 借款金额将全部用于实施募投项目"新药研发项目"，不得用作其他用途。公司 可根据募投项目实际需求分期向众生睿创提供借款，借款期限为 5 年，借款利率 参考同期的全国银行间同业拆借中心发布的贷款市场报价利率（LPR），众生睿 创可视其实际经营情况和公司协商延期或提前偿还公司借款。董事会授权公司董 事长或其指定授权代理人办理相关事项及签署有关文件。具体情况如下： 证券代码： ...